This video introduces a novel CRISPR-based gene editing strategy that enables in vivo, cell-type specific therapeutic delivery. The approach utilizes an engineered delivery vehicle comprising a viral protein capsule fused with a small antibody designed to specifically target proteins on a cell type of interest. This modular system was demonstrated to deliver Cas9 and guide RNA, achieving specific delivery and editing in vitro. In mice, the strategy successfully generated functional CAR-T cells in vivo that targeted and killed cancer cells, and also facilitated some Cas9-mediated gene editing. A key advantage is its adaptability, allowing for the incorporation of different antibodies to achieve dual functionalities like specific delivery and cell proliferation signaling, making it a promising and generalizable platform for various gene therapies, including accelerated CAR-T cell production.
In Vivo Cell-Type Specific Gene Editing for Advanced Therapies
0:00 Novel CRISPR Gift: Introduction of a new CRISPR-enabled method for in vivo, cell-type specific gene editing.
0:05 Addressing Gene Therapy Challenges: This strategy tackles the significant challenge of cell-type specific therapeutic delivery in gene therapy.
0:11 Accelerating CAR-T Production: A potential major application is the same-day administration of highly effective CAR-T cells for blood cancers, a process that typically takes over a month.
0:21 Engineered Delivery Vehicle: The core innovation is a delivery vehicle that can be easily engineered to target specific cell types.
0:29 Vehicle Components: It consists of a viral protein capsule, commonly used in gene therapies, with a small antibody fused to its exterior. This antibody binds to a specific protein displayed only on the target cell type.
0:40 In Vitro Efficacy: Particles loaded with Cas9 and a guide RNA achieved specific delivery to target cells and good editing efficiency in vitro.
0:50 Versatile Antibody Selection: A key feature is the ability to attach various antibodies. For example, a mixture of antibodies can specifically deliver cargo to T-cells and signal for their proliferation, which is highly beneficial for T-cell therapies.
1:03 In Vivo Functional CAR-T Generation: In mouse models, the strategy successfully delivered a CAR-T payload and Cas9 into the genome, leading to the in vivo creation of functional CAR-T cells that effectively killed target cells.
1:18 Editing Levels and Generalizability: While Cas9 editing levels were relatively low, the strategy is deemed "really cool" due to its generalizability to target other specific cell types, despite similar in vivo CAR-T generation claims by others.